|
|
|
|
|
|
|
|
|
|
| 09:00 - 09:35 | welcome coffee and snacks |
| 09:35 - 09:55 |
Opening speeches
Dean of University of Pécs, Prof. Sámuel Komoly, Prof. Zsolt Illés |
| 09:55 - 10:25 |
Biology and immunology of NMO
Bernhard Hemmer Munich, Germany |
| 10:25 - 10:55 |
Pathology and animal models of NMO
Hans Lassmann H. Vienna, Austria |
| 10:55 - 11:25 |
Testing for auto-antibodies in NMO
Roberto Furlan Milan, Italy |
| 11:25 - 11:55 |
Clinical aspects and guidelines in NMO
Zsolt Illés Pécs, Hungary |
| 12:00 - 13:00 | Lunch |
| 13:00 - 13:30 |
The widening spectrum of antibody-mediated neurological diseases: from neuromuscular junction to brain
Angela Vincent Oxford, UK |
| 13:30 - 14:00 |
Novel concepts and guidelines of paraneoplastic neurological syndromes
Jerome Honnorat Lyon, France |
| 14:00 - 14:30 |
Antibodies against CNS receptors
Klaus-Peter Wandinger Lübeck, Germany |
| 14:30 - 15:00 |
Stiff-person syndrome
Trygve Holmoy Oslo, Norway |
| 15:00 - 15:20 | Coffee break |
| 15:20 - 15:50 |
Basic concepts: NMJ and the role of thymus
Camilla Buckley, Angela Vincent Oxford, UK |
| 15:50 - 16:20 |
AchR-MG, MuSK-MG and SN-MG
Angela Vincent Oxford, UK |
| 16:20 - 16:50 |
Treatment options in MG
Samuel Komoly Pécs, Hungary |
| 16:50 - 17:20 |
Clinical aspects of MG in the elderly
Csilla Rózsa Budapest, Hungary |
| 19:30 - 23:00 |
Dinner
Real hungarian dinner and music in the authentic Tenkes Csárda. Buses start at 19.00 from Hotel Palatinus (conference venue) and Hotel Corso. |
| 09:00 - 09:30 |
Proteomic and lipidomiccharacterization of autoimmune demyelinating diseases
William Robinson Stanford, USA |
| 09:30 - 09:55 |
Future dimensions in MS therapy
Hans-Peter Hartung Düsseldorf, Germany |
| 09:55 - 10:15 |
Pathogenetic considerations and autoantibodies in MS
Robert Weissert Geneve, Switzerland |
| 10:15 - 10:40 |
Neutralizing antibodies
Jacek Losy Posnan, Poland |
| 10:40 - 10:50 | Coffee break |
| 10:50 - 11:15 |
Natalizumab in the clinical practice
Thomas Berger Innsbruck, Austria |
| 11:15 - 11:40 |
Alemtuzumab: a promising treatment in MS
Alastair Compston Cambridge, UK |
| 11:40 - 12:05 |
Daclizumab in MS
Heinz Wiendl Münster, Germany |
| 12:05 - 12:30 |
New mode of action: role of SP1-receptor modulation in multiple sclerosis
Ludwig Kappos Basel, Switzerland |
| 12:30 - 12:55 |
Balancing risks and benefits in newly emerging therapies for MS
Ron Milo Ashkelon, Israel |
| 12:55 - 13:20 |
Fampridine
Jana Preiningerova Prague, Czech Republic |
| 13:20 - 13:45 |
IVIG in MS and neuroimmunological diseases
Juan Archelos Graz, Austria |
| 13:45 - 13:55 | Closing remarks |
| 13:55 - 15:00 | Farewell lunch |
